Showing results (221-230 of 432) with videos related to

Sort By:
Pageof 44
Haematologica|January 22, 2026
Imetelstat improves patient-reported outcomes and quality of life in lower-risk myelodysplastic syndromes: results from the phase III IMerge studyMikkael A Sekeres, Amer M Zeidan, Valeria Santini, et al.
Biomedicine Hub|February 10, 2021
Time for Change? The Why, What and How of Promoting Innovation to Tackle Rare Diseases - Is It Time to Update the EU's Orphan Regulation? And if so, What Should be Changed?Denis Horgan, Barbara Moss, Stefania Boccia, et al.
Haematologica|October 3, 2009
TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemiaOlivier Kosmider, Véronique Gelsi-Boyer, Marion Ciudad, et al.
Leukemia Research|July 1, 2011
Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experienceFabien Le Bras, Marie Sebert, Charikleia Kelaidi, et al.
Blood|June 22, 2011
Comparison of high-dose cytarabine and timed-sequential chemotherapy as consolidation for younger adults with AML in first remission: the ALFA-9802 studyXavier Thomas, Mohamed Elhamri, Emmanuel Raffoux, et al.
European Journal of Haematology|September 16, 2018
Inflammatory disorders associated with trisomy 8-myelodysplastic syndromes: French retrospective case-control studyNadege Wesner, Louis Drevon, Alexis Guedon, et al.
British Journal of Haematology|December 15, 2005
A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Français des MyélodysplasiesDidier Bouscary, Laurence Legros, Micheline Tulliez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 6, 2009
Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experienceCharikleia Kelaidi, Sylvie Chevret, Stéphane De Botton, et al.
Mediterranean Journal of Hematology and Infectious Diseases|November 16, 2011
Treatment of Acute Promyelocytic Leukemia with AIDA Based Regimen. Update of a Tunisian Single Center StudyRamzi Jeddi, Hèla Ghédira, Ramzi Ben Amor, et al.
Blood|April 1, 2004
Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trialNicole Casadevall, Pierre Durieux, Stéphanie Dubois, et al.
Pageof 44